Subcutaneous vs Intravenous Trastuzumab for ERBB2-Positive Early Breast Cancer

Leggi l'articolo originale


This final analysis of the phase 3 randomized clinical trial HannaH evaluates the efficacy and safety of subcutaneous trastuzumab compared with that of intravenous trastuzumab for patients with ERBB2-positive early breast cancer after 6 years’ follow-up.

Lascia un commento